EHA 2021 | CD123 targeted therapies for hematologic malignancies
Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, gives an overview of treatments targeting CD123 in patients with diverse myeloid malignancies. Dr Pemmaraju discusses the approval of tagraxofusp, a CD123-directed immunotherapy approved for the treatment of blastic plasmacytoid dendritic cell neoplasm, and it’s expansion into other hematologic malignancies, as well as commenting on novel CD123-tagergting agents, such as IMGN632, and combinatorial approaches. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Naveen Pemmaraju, MD, is a member of the ASH Communications Committee and the ASCO Leukemia Advisory panel; has participated in consultancy work for Pacylex Pharmaceuticals, ImmuniGen, Bristol Myers Squibb, Blueprint Medicines, Clearview Healthcare Partners, Astellas Pharma US Inc., Triptych Health Partners and CTI Biopharma; has received grants from Affymetrix and SagerStrong Foundation; has received honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Diagnostics, Blueprint Medicines, DAVA Oncology, Springer Science + Business Media LLC, Aptitude Health, NeoPharm Israel and CareDx, Inc., has received research support from Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Affymetrix, Daiichi Sankyo and Plexxikon; and has received travel reimbursement from Stemline Therapeutics, Celgene, MustangBio, DAVA Oncology and AbbVie.
